Scleroderma
Scleroderma
Search
Our Innovation Prize | Partnering
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
Brigitte Fuhr
Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.
Alex Breiner
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
See our Locations
We offer career development opportunities in over 170 locations across the world. Explore some of our featured locations.
Boehringer Ingelheim - Life Forward
Boehringer Ingelheim is one of the world’s leading familyowned pharmaceutical companies,developing medicines to address unmet needs in human and animal
Top-line Phase II Data for treatment of MASH
Boehringer Ingelheim and Zealand Pharma announced top-line Phase II data for treatment of metabolic dysfuntion-associated steatohepatitis (MASH).
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
Lung Diseases
Our Therapeutic Areas
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
More Potential
More Potential
Benefits & Rewards
We invest in our people so they will stay and grow with us. We offer benefits such as rewards and development opportunities to help retain employees.
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)
FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US
FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
A Planned Safety Net for Patients in Need
A Planned Safety Net for Patients in Need
Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)
Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Management Rotation
Click here to read testimonies from our employees who enrolled in our management rotation program.
Partnering Interests
Partnering Interests
Experience our culture during your interview process
Discover if our company is the right fit for you.
From Finance to Pharma
From Finance to Pharma
Embracing Differences: Our journey to diversity, equity, and inclusion
Embracing Differences: Our journey to diversity, equity, and inclusion
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.